diacetamate: cpd is acetaminophen acetate
ID Source | ID |
---|---|
PubMed CID | 17499 |
CHEMBL ID | 2106185 |
SCHEMBL ID | 863106 |
MeSH ID | M0092874 |
Synonym |
---|
diacetamat |
nsc6083 |
acetamide, n-[4-(acetyloxy)phenyl]- |
2623-33-8 |
acetanilide, acetate (ester) |
acetaminophen acetate |
nsc-6083 |
4-acetamidophenyl acetate |
p-acetoxyacetanilide |
n-acetyl-4-aminophenyl acetate |
4-acetoxyacetanilide |
diacetamate |
nsc33893 |
nsc-33893 |
AG-670/32634053 |
4-(acetylamino)phenyl acetate |
NCGC00160605-01 |
MAYBRIDGE1_006198 |
inchi=1/c10h11no3/c1-7(12)11-9-3-5-10(6-4-9)14-8(2)13/h3-6h,1-2h3,(h,11,12 |
4'-acetoxyacetanilide |
A0067 |
n,o-diacetyl-4-aminophenol |
STL034244 |
HMS559B16 |
(4-acetamidophenyl) acetate |
FT-0661040 |
AKOS002255264 |
HMS3264O15 |
ai3-17250 |
diacetamatum [inn-latin] |
bfg1ty61bg , |
acetamide, n-(4-(acetyloxy)phenyl)- |
nsc 33893 |
diacetamatum |
einecs 220-077-6 |
diacetamate [inn:ban] |
unii-bfg1ty61bg |
diacetamato |
nsc 6083 |
acetanilide, 4'-hydroxy-, acetate (ester) |
diacetamato [inn-spanish] |
dtxsid2046256 , |
tox21_111931 |
dtxcid0026256 |
cas-2623-33-8 |
nsc-758889 |
pharmakon1600-01504515 |
nsc758889 |
CHEMBL2106185 |
n,o-diacetyl-4-aminopheno |
F3228-0190 |
acetaminophen acetate (acetaminophen impurity) |
4'-hydroxyacetanilide acetate |
o-acetylparacetamol |
n-[4-(acetyloxy)phenyl]acetamide |
acetamide,n-[4-(acetyloxy)phenyl]- |
paracetamol impurity h [ep impurity] |
diacetamate [inn] |
SCHEMBL863106 |
CCG-213946 |
MLS006011695 |
smr002530013 |
acetanilide, 4'-hydroxy-, acetate |
AB01563223_01 |
VU0606051-1 |
mfcd00059205 |
o,n-diacetyl-4-aminophenol |
SR-01000872731-1 |
sr-01000872731 |
4-(acetylamino)phenyl acetate (n,o-diacetyl-4-aminophenol) |
J-016335 |
SBI-0207076.P001 |
3-(4-methylbenzoyl)acrylicacid |
F17539 |
CS-0005650 |
HY-66004 |
acetic acid 4-acetylamino-phenyl ester |
AS-48014 |
BRD-K93611241-001-01-4 |
Q27274637 |
EN300-7392397 |
Z29109552 |
SY105212 |
Excerpt | Reference | Relevance |
---|---|---|
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
AID504749 | qHTS profiling for inhibitors of Plasmodium falciparum proliferation | 2011 | Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043 | Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 2 (40.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (40.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (33.42) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |